Skip to main content

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Publication ,  Journal Article
Greenberg, PL; Attar, E; Bennett, JM; Bloomfield, CD; De Castro, CM; Deeg, HJ; Foran, JM; Gaensler, K; Garcia-Manero, G; Gore, SD; Head, D ...
Published in: J Natl Compr Canc Netw
January 2011

These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.(116,119,120,128,129) Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 2011

Volume

9

Issue

1

Start / End Page

30 / 56

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Myelodysplastic Syndromes
  • Humans
  • Clinical Trials as Topic
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … National Comprehensive Cancer Network, . (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw, 9(1), 30–56. https://doi.org/10.6004/jnccn.2011.0005
Greenberg, Peter L., Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H Joachim Deeg, James M. Foran, et al. “NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.J Natl Compr Canc Netw 9, no. 1 (January 2011): 30–56. https://doi.org/10.6004/jnccn.2011.0005.
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan;9(1):30–56.
Greenberg, Peter L., et al. “NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.J Natl Compr Canc Netw, vol. 9, no. 1, Jan. 2011, pp. 30–56. Pubmed, doi:10.6004/jnccn.2011.0005.
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O’Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan;9(1):30–56.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 2011

Volume

9

Issue

1

Start / End Page

30 / 56

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Myelodysplastic Syndromes
  • Humans
  • Clinical Trials as Topic
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis